AstraZeneca

News

AZ/Merck & Co's Lynparza sets 'new standards' in ovarian can...

AstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US cancer experts reviewing long-term trial data.

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

AstraZeneca to unveil key data for cancer drugs at ASCO

AstraZeneca plans to unveil data at this year’s American Society of Clinical Oncology (ASCO) conference that could expand the number of patients who could be treated with two of its most im

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AZ/Merck & Co's ovarian cancer drug gets wider US licence

AstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to be used in a wider group of ovarian cancer patients when combined with Roche’s

News

FDA approves new heart failure use for AZ's Farxiga

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fract

News

GSK takes fight to AZ/Merck & Co with first-line ovarian can...

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class

News

AZ maintains 2020 guidance as Q1 sales grow despite pandemic

The ongoing pandemic will not affect AstraZeneca’s performance in 2020, the company has said after its first quarter results beat analysts’ expectations.

AZ/Merck & Co's Lynparza sets 'new standards' in ovarian can...

AstraZeneca to unveil key data for cancer drugs at ASCO

AZ/Merck & Co's ovarian cancer drug gets wider US licence

FDA approves new heart failure use for AZ's Farxiga

GSK takes fight to AZ/Merck & Co with first-line ovarian can...

AZ maintains 2020 guidance as Q1 sales grow despite pandemic

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks